Product Program year 2023 Source: CMS Open Payments

Zaltrap

Biological Oncology

NDC 0024-5840-01

Open in the dashboard

General payments

$13,168

5 payments

Research payments

$60,380

7 payments

Through program year 2023, $13,168 in general payments and $60,380 in research payments were reported against Zaltrap (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Amount Payments
2023 General $5,660 4
2020 Research $60,380 7
2019 General $7,508 1

Breakdown

Who paid General payments · program years 2019–2023
  1. Genzyme Corporation $7,508 1 payment
  2. Sanofi-Aventis U.S. LLC $5,660 4 payments
Top recipients General payments · program year 2023
  1. Axel Grothey Hematology & Oncology · Germantown, TN $1,568 28% · 1 payment
  2. Richard Kim Hematology & Oncology · Tampa, FL $1,568 28% · 1 payment
  3. Edmund Kopetz Medical Oncology · Houston, TX $1,442 25% · 1 payment
  4. Tanios Bekaii-Saab Hematology & Oncology · Scottsdale, AZ $1,082 19% · 1 payment

Each share is of general payments naming this product in 2023.

Specialties paid General payments · program year 2023
  1. Hematology & Oncology Internal Medicine $4,218 75% · 3 practitioners
  2. Medical Oncology Internal Medicine $1,442 25% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2023
  1. Florida $1,568 28% · 1 recipient
  2. Tennessee $1,568 28% · 1 recipient
  3. Texas $1,442 25% · 1 recipient
  4. Arizona $1,082 19% · 1 recipient

Each share is of general payments naming this product in 2023 where a state was reported.

5 general · 7 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record